Compare Organon & Co. Common Stock (OGN) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Invesco Solar ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Invesco Solar ETF trades at $42.4 (market cap $881.52M). The key difference: Organon & Co. Common Stock is far larger — about 4.1× Invesco Solar ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Invesco Solar ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Invesco Solar ETF for 35 Days on average.
| OGN | TAN | |
|---|---|---|
Market Cap | $3.62B | $881.52M |
Volume | 2,892,999 | 3,915,267 |
Sector | Health | Sector/Thematic |
52-Week High | $13.81 | $73.95 |
52-Week Low | $5.70 | $42.64 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TAN trades at $44.38, up 2.07% today but facing bearish technical signals with sell signals outweighing buys 11-8. The solar ETF shows mixed sentiment amid sector volatility, with recent news highlighting both policy tailwinds from U.S. tariffs and headwinds from high borrowing costs impacting project financing.
Outlook remains cautious due to sector-specific risks including interest rate sensitivity and market saturation concerns. While geopolitical shifts favor renewable energy adoption, TAN's high expense ratio and historical underperformance versus broad market indices present challenges for investors seeking stable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
